General and IgH locus-specific genomic instability in stimulated Polζf/Δ/CD21-cre B cells measured by FISH
| General genome instability | IgH locus-specific instability | ||||||
| Genotype | Cytokine stimulation | Percentage of IgG1+ cells on day 4 | Number of metaphases analyzed | Number of chromosomal aberrations | Number of metaphases with chromosomal breaks (%) | Number of metaphases analyzed | Number of metaphases with breaks in the IgH locus (%) |
| Polζf/+ | α-CD40 + IL-4 | 30.3 | 30 | 1 | 1 (3) | 50 | 1 (2) |
| CD21-cre | α-CD40 + IL-4 | 36.1 | 30 | 2 | 2 (7) | 50 | 2 (4) |
| Polζf/+/CD21-cre | α-CD40 + IL-4 | 28.4 | 30 | 8 | 7 (23) | 50 | 1 (2) |
| Polζf/+/CD21-cre | α-CD40 + IL-4 | 26.1 | 30 | 9 | 8 (27) | 50 | 1 (2) |
| Polζf/+/CD21-cre | α-CD40 + IL-4 | 32.6 | 30 | 5 | 5 (17) | 50 | 1 (2) |
| Polζf/+/CD21-cre | α-CD40 + IL-4 | 34.7 | 30 | 2 | 2 (7) | 50 | 1 (2) |
| Polζf/+/CD21-cre | α-CD40 + IL-4 | 23.7 | 30 | 3 | 2 (7) | 50 | 0 (0) |
| Polζf/+/CD21-cre | α-CD40 | 1.0 | ND | ND | ND | 50 | 0 (0) |
| Polζf/+/CD21-cre | α-CD40 | 0.1 | 28 | 1 | 1 (3) | 50 | 0 (0) |
| Polζf/+/CD21-cre | α-RP105 | 0.2 | 22 | 0 | 0 (0) | 50 | 0 (0) |
| Polζf/Δ/CD21-cre | α-CD40 + IL-4 | 16.7 | 30 | 47 | 24 (80) | 50 | 5 (10) |
| Polζf/Δ/CD21-cre | α-CD40 + IL-4 | 13.0 | 30 | 41 | 20 (67) | 50 | 5 (10) |
| Polζf/Δ/CD21-cre | α-CD40 + IL-4 | 19.5 | 30 | 30 | 16 (53) | 50 | 3 (6) |
| Polζf/Δ/CD21-cre | α-CD40 + IL-4 | 16.6 | 30 | 35 | 14 (47) | 50 | 3 (6) |
| Polζf/Δ/CD21-cre | α-CD40 + IL-4 | 16.8 | 30 | 16 | 10 (33) | 50 | 4 (8) |
| Polζf/Δ/CD21-cre | α-CD40 + IL-4 | 18.0 | 30 | 19 | 11 (37) | 50 | 5 (10) |
| Polζf/Δ/CD21-cre | α-CD40 | 0.5 | 30 | 18 | 13 (43) | 50 | 0 (0) |
| Polζf/Δ/CD21-cre | α-CD40 | 0.1 | 20 | 10 | 7 (35) | 50 | 0 (0) |
| Polζf/Δ/CD21-cre | α-CD40 | 0.1 | 23 | 1 | 1 (4) | 50 | 0 (0) |
| Polζf/Δ/CD21-cre | α-RP105 | 0.1 | 30 | 29 | 20 (67) | 50 | 0 (0) |
| Polζf/Δ/CD21-cre | α-RP105 | 0.1 | 30 | 31 | 15 (50) | 50 | 0 (0) |
| General genome instability | IgH locus-specific instability | ||||||
| Genotype | Cytokine stimulation | Percentage of IgG1+ cells on day 4 | Number of metaphases analyzed | Number of chromosomal aberrations | Number of metaphases with chromosomal breaks (%) | Number of metaphases analyzed | Number of metaphases with breaks in the IgH locus (%) |
| Polζf/+ | α-CD40 + IL-4 | 30.3 | 30 | 1 | 1 (3) | 50 | 1 (2) |
| CD21-cre | α-CD40 + IL-4 | 36.1 | 30 | 2 | 2 (7) | 50 | 2 (4) |
| Polζf/+/CD21-cre | α-CD40 + IL-4 | 28.4 | 30 | 8 | 7 (23) | 50 | 1 (2) |
| Polζf/+/CD21-cre | α-CD40 + IL-4 | 26.1 | 30 | 9 | 8 (27) | 50 | 1 (2) |
| Polζf/+/CD21-cre | α-CD40 + IL-4 | 32.6 | 30 | 5 | 5 (17) | 50 | 1 (2) |
| Polζf/+/CD21-cre | α-CD40 + IL-4 | 34.7 | 30 | 2 | 2 (7) | 50 | 1 (2) |
| Polζf/+/CD21-cre | α-CD40 + IL-4 | 23.7 | 30 | 3 | 2 (7) | 50 | 0 (0) |
| Polζf/+/CD21-cre | α-CD40 | 1.0 | ND | ND | ND | 50 | 0 (0) |
| Polζf/+/CD21-cre | α-CD40 | 0.1 | 28 | 1 | 1 (3) | 50 | 0 (0) |
| Polζf/+/CD21-cre | α-RP105 | 0.2 | 22 | 0 | 0 (0) | 50 | 0 (0) |
| Polζf/Δ/CD21-cre | α-CD40 + IL-4 | 16.7 | 30 | 47 | 24 (80) | 50 | 5 (10) |
| Polζf/Δ/CD21-cre | α-CD40 + IL-4 | 13.0 | 30 | 41 | 20 (67) | 50 | 5 (10) |
| Polζf/Δ/CD21-cre | α-CD40 + IL-4 | 19.5 | 30 | 30 | 16 (53) | 50 | 3 (6) |
| Polζf/Δ/CD21-cre | α-CD40 + IL-4 | 16.6 | 30 | 35 | 14 (47) | 50 | 3 (6) |
| Polζf/Δ/CD21-cre | α-CD40 + IL-4 | 16.8 | 30 | 16 | 10 (33) | 50 | 4 (8) |
| Polζf/Δ/CD21-cre | α-CD40 + IL-4 | 18.0 | 30 | 19 | 11 (37) | 50 | 5 (10) |
| Polζf/Δ/CD21-cre | α-CD40 | 0.5 | 30 | 18 | 13 (43) | 50 | 0 (0) |
| Polζf/Δ/CD21-cre | α-CD40 | 0.1 | 20 | 10 | 7 (35) | 50 | 0 (0) |
| Polζf/Δ/CD21-cre | α-CD40 | 0.1 | 23 | 1 | 1 (4) | 50 | 0 (0) |
| Polζf/Δ/CD21-cre | α-RP105 | 0.1 | 30 | 29 | 20 (67) | 50 | 0 (0) |
| Polζf/Δ/CD21-cre | α-RP105 | 0.1 | 30 | 31 | 15 (50) | 50 | 0 (0) |
Each row represents the results from one individual mouse.